Find Funding Opportunities

Find Funding Opportunities

Returning 20 results

Notice of NINDS Programmatic Priority for PAR-13-208 "Countermeasures Against Chemical Threats (CounterACT) Cooperative Research Projects (U01)"

NOT
Thursday, August 6, 2015
Saturday, January 1, 2022
NOT-NS-15-035

Funding Opportunity Purpose

Notice NINDS Programmatic Priority PAR-13-208 Countermeasures Against Chemical Threats CounterACT) Cooperative Research Projects U01)" Notice Number: NOT-NS-15-035 Key Dates Release Date:   August 6, 2015 Related Announcements PAR-13-208     Issued National Institute Neurological Disorders Stroke NINDS) Purpose Notice to inform potential applicants PAR-13-208 quot;Countermeasures Against Chemical Threats CounterACT) Cooperative Research Projects (U01)" priority be given research applications clearly describe goal developing or therapeutic candidates is ready advanced development the end the proposed project periods to 5 years).  Projects proposed will given priority should culminate the submission a Pre-Investigational New Drug Pre-IND) Application Package the FDA, should very close securing the data planning needed submission the Pre-IND package.  such, applicants encouraged address regulatory strategy necessary achieve goal. Research supported under FOA to prepare advanced development after filing Pre-IND package.  Most the advanced development activities required regulatory approval include GMP GLP level efforts) not usually covered under FOA, could potentially supported other federal agencies industry once NIH-supported research completed.  HHS advanced development agency relevant this FOA the Biomedical Advanced Research Development Authority BARDA). Once research funded under FOA completed, should the following before exploring possibility additional funding through BARDA advanced development. least lead compound. Lead compounds biologically active compounds hits where affinity, potency, selectivity been established. Efficacy an appropriate animal model Initial pharmacology toxicology studies Stable scalable synthesis the lead compound Preliminary regulatory strategy including Target Product Profile regulatory expertise Commercialization plan other indications applicable Intellectual Property Rights Applications focus specifically the above goal be deemed high programmatic priority. applicants strongly encouraged discuss applications the Scientific/Research contact listed the FOA early the application development process. Inquiries Please direct inquiries to: David A. Jett, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone: 301-443-8189 Email: jettd@ninds.nih.gov

Notice of Programmatic Priority for NINDS for PAR-15-146 "Countermeasures Against Chemical Threats (CounterACT) Centers of Excellence (U54)"

NOT
Thursday, August 6, 2015
Saturday, January 1, 2022
NOT-NS-15-036

Funding Opportunity Purpose

Notice Programmatic Priority NINDS PAR-15-146 Countermeasures Against Chemical Threats CounterACT) Centers Excellence U54)" Notice Number: NOT-NS-15-036 Key Dates Release Date:   August 6, 2015 Related Announcements PAR-15-146 Issued National Institute Neurological Disorders Stroke NINDS) Purpose Notice to inform potential applicants PAR-15-146 quot;Countermeasures Against Chemical Threats CounterACT) Centers Excellence (U54)" priority be given research applications clearly describe goal developing or therapeutic candidates is ready advanced development the end the proposed project periods to 5 years).  Projects proposed response this FOA will given programmatic priority should culminate the submission a Pre-Investigational New Drug Pre-IND) Application Package the FDA, should very close securing the data planning needed submission the Pre-IND package.  such, applicants encouraged address regulatory strategy necessary achieve goal. Research supported under FOA to prepare advanced development after filing Pre-IND package.  Most the advanced development activities required regulatory approval include GMP GLP level efforts) not usually covered under FOA, could potentially supported other federal agencies industry once NIH-supported research completed.  HHS advanced development agency relevant this FOA the Biomedical Advanced Research Development Authority BARDA). Once research funded under FOA completed, should the following before exploring possibility additional funding through BARDA advanced development. least lead compound. Lead compounds biologically active compounds hits where affinity, potency, selectivity been established. Efficacy an appropriate animal model Initial pharmacology toxicology studies Stable scalable synthesis the lead compound Preliminary regulatory strategy including Target Product Profile regulatory expertise Commercialization plan other indications applicable Intellectual Property Rights Applications focus specifically the above goal be deemed high programmatic priority. applicants strongly encouraged discuss applications the Scientific/Research contact early the application development process. Inquiries Please direct inquiries to: David A. Jett, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone: 301-443-8189 Email: jettd@ninds.nih.gov

Notice of Pre-application Informational Webinar for PAR-15-146 "Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54)"

NOT
Friday, June 12, 2015
Saturday, January 1, 2022
NOT-NS-15-030

Funding Opportunity Purpose

Notice Pre-application Informational Webinar PAR-15-146 Countermeasures Against Chemical Threats CounterACT) Research Centers Excellence U54)" Notice Number: NOT-NS-15-030 Key Dates Release Date:   June 12, 2015 Related Announcements PAR-15-146 Issued National Institute Neurological Disorders Stroke NINDS) Purpose Notice to inform potential applicants PAR-15-146 quot;Countermeasures Against Chemical Threats CounterACT) Research Centers Excellence U54)" a pre-application webinar provide submission information this FOA. NIH CounterACT program supports research the development new improved medical countermeasures designed prevent treat conditions caused acute exposure chemical agents www.ninds.nih/counteract). NIH CounterACT research network includes Research Centers Excellence, individual research projects, contracts, other programs. Currently NIH soliciting proposals new renewal U54 Research Centers Excellence. webinar provide information preparing research proposals will include information eligibility, scientific scope, Center structure, application instructions, grants management, well time questions the audience answers the NIH staff. intent the webinar to provide overview the initiative to address questions pertinent preparing applications. webinar optional not required application submission. Webinar Information Date:                            Friday, July 17, 2015 Time:                           1:00 pm ET Meeting URL:               CounterACT Center Webinar Questions be submitted email sarah.norring@nih.gov before webinar; Please include quot;U54 Webinar Question" the subject line. While every effort be to answer questions during webinar itself, due time constraints responses be sent afterwards. applicants strongly encouraged discuss applications the Scientific/Research contact early the application development process. complete text the FOA available http://grants.nih.gov/grants/guide/pa-files/PAR-15-146.html. Inquiries Please direct inquiries to: Sarah A. Norring, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone: 301-443-8189 Email: sarah.norring@nih.gov

Notice of Participation of Additional NIH Institutes and Centers in PAR-13-208 Countermeasures Against Chemical Threats (CounterACT) Cooperative Research Projects (U01)

NOT
Tuesday, May 14, 2013
Saturday, January 1, 2022
NOT-NS-13-029

Funding Opportunity Purpose

Notice Participation Additional NIH Institutes Centers PAR-13-208 Countermeasures Against Chemical Threats CounterACT) Cooperative Research Projects U01) Notice Number: NOT-NS-13-029 Key Dates Release Date: 14, 2013 Related Announcements PAR-13-208 Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this Notice to inform potential applicants the participation additional NIH Institutes, effective immediately, Funding Opportunity Announcement FOA) PAR-13-208. following sections PAR-13-208 been updated reflect participation NEI, NIAID, NIAMS, NIEHS this FOA. Part 1. Overview Information Components Participating Organizations National Institute Neurological Disorders Stroke NINDS) National Eye Institute NEI) National Institute Allergy Infectious Diseases NIAID) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Environmental Health Sciences NIEHS) National Institute General Medical Sciences NIGMS) Catalog Federal Domestic Assistance CFDA) Number(s) 93.853; 93.867; 93.855; 93.856; 93.846; 93.113; 93.859  Part 2. Section VII. Agency Contacts Scientific/Research Contact(s)       Houman Araj, Ph.D. National Eye Institute NEI) Telephone: 301-451-2020 Email: arajh@nei.nih.gov Gennady E. Platoff Jr., Ph.D. National Institute Allergy amp; Infectious Diseases NIAID) Telephone: 301-451-4418 Email: platoffg@niaid.nih.gov Hung Tseng, Ph.D. National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) Telephone: 301-594-5032 Email: tsengh@mail.nih.gov Srikanth S. Nadadur, Ph.D. National Institute Environmental Health Sciences NIEHS) Telephone: 919-541-5327 Email: nadadurs@niehs.nih.gov Financial/Grants Management Contact(s) William W. Darby Grants Management Branch National Eye Institute NEI) Telephone: 301-451-2020 Email: darbyw@mail.nih.gov Victoria Connors Grants Management Branch National Institute Allergy amp; Infectious Diseases NIAID) Telephone: 301-402-5065 Email: connorssv@niaid.nih.gov Melinda B. Nelson Grants Management Branch National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) Telephone: 301-435-5278 Email: nelson@mail.nih.gov Lisa Archer Edwards, MBA Grants Management Branch National Institute Environmental Health Sciences NIEHS) Telephone: 919-541-0751  Email:  archer@niehs.nih.gov Inquiries Please direct inquiries to: David A. Jett, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-6035  Email: jettd@ninds.nih.gov

Notice of Intent to Publish a Funding Opportunity Announcement for Countermeasures Against Chemical Threats (CounterACT) Cooperative Research Projects (U01)

NOT
Thursday, December 20, 2012
Saturday, January 1, 2022
NOT-NS-13-004

Funding Opportunity Purpose

Notice Intent Publish Funding Opportunity Announcement Countermeasures Against Chemical Threats CounterACT) Cooperative Research Projects U01) Notice Number: NOT-NS-13-004 Key Dates Release Date: December 20, 2012 Estimated Publication Date Announcement: 1, 2013  First Estimated Application Due Date: September 16, 2013   Earliest Estimated Award Date: July 1, 2014  Earliest Estimated Start Date: July 1, 2014 Issued National Institute Neurological Disorders Stroke NINDS) Purpose National Institute Neurological Disorders Stroke NINDS), intends re-issue Program Announcement Special Review Considerations PAR) solicit applications ldquo;Countermeasures Against Chemical Threats CounterACT) Cooperative Research Projects U01)”. goal this initiative to provide support translational research develop therapeutics reducing mortality morbidity caused acute exposures chemical threat agents. Chemical threats toxic chemicals could used a terrorist attack accidentally released industrial production, storage shipping.  scope the research supported within milestone-driven translational program includes target candidate identification characterization, through candidate optimization demonstration in vivo efficacy, through Investigational New Drug IND) submission.   www.ninds.nih.gov/counteract a description the CounterACT program.  Notice being provided allow potential applicants sufficient time develop meaningful collaborations competitive research programs.  FOA expected be published Spring 2013 an expected application due date September 2013. FOA utilize U01 activity code. Details the planned FOA provided below. Research Initiative Details Notice encourages collaborative multidisciplinary investigations, combining expertise toxicology drug discovery development, discover develop new improved therapeutics treating victims chemical exposures. CounterACT research program utilize Research Project - Cooperative Agreements U01) support Research Projects up 5 years translational research.  research project must establish milestones include discrete quantitative goals create or no-go decision points the project.  Chemical threats be covered include chemical warfare agents e.g. sarin, VX), Toxic Industrial Chemicals e.g. phosgene, sulfur dioxide) others. Please contact NIH Program Director below discuss chemical threats be covered.  NIH intends commit approximately 2-3 million per year Fiscal Years 2014, 2015, 2016 fund new and/or competing renewal U01 awards.  Since nature scope the proposed research vary application application, is anticipated the size duration each award also vary. total amount awarded the number awards depend the number, quality, duration, costs the applications received.  is anticipated several NIH Institutes, including National Eye Institute NEI), National Institute Allergy Infectious Diseases NIAID), National Institute Arthritis Musculoskeletal Skin Diseases NIAMS), Eunice Kennedy Shriver National Institute Child Health Human Development NICHD), National Institute Environmental Health Sciences NIEHS), the National Institute General Medical Sciences NIGMS), also participate this funding opportunity announcement.  APPLICATIONS NOT BEING SOLICITED THIS TIME. Inquiries Please direct inquiries to: David A. Jett, Ph.D. Program Director, NIH CounterACT Research National Institutes Health, NINDS 6001 Executive Blvd. NSC, Room 2177, MSC 9527 Bethesda, MD 20892-9527 Telephone: 301-496-6035 Fax: 301-402-1501 Email: jettd@ninds.nih.gov

Notice of Intent to Publish Funding Opportunity Announcements for Countermeasures Against Chemical Threats (CounterACT) Cooperative Research Projects (U01) and Research Centers of Excellence (U54)

NOT
Friday, March 5, 2010
Saturday, January 1, 2022
NOT-NS-10-011

Funding Opportunity Purpose

Notice Intent Publish Funding Opportunity Announcements Countermeasures Against Chemical Threats CounterACT) Cooperative Research Projects U01) Research Centers Excellence U54) Notice Number: NOT-NS-10-011 Key Dates Release Date: March 5, 2010 Issued National Institute Neurological Disorders Stroke NINDS) http://www.ninds.nih.gov) Purpose nbsp; National Institute Neurological Disorders Stroke NINDS) intends issue Funding Opportunity Announcements FOAs) the spring 2010: ldquo;Countermeasures Against Chemical Threats CounterACT) Research Centers Excellence U54)” ldquo;Countermeasures Against Chemical Threats CounterACT) Cooperative Research Projects U01)”.  goal both initiatives to provide support translational research develop therapeutics reducing mortality morbidity caused acute exposures chemical threat agents. Chemical threats toxic chemicals could used a terrorist attack accidentally released industrial production, storage shipping.  scope the research supported within milestone-driven translational program includes target candidate identification characterization, through candidate optimization demonstration in vivo efficacy, through Investigational New Drug IND) submission clinical trials appropriate.   www.ninds.nih.gov/counteract a description the CounterACT program.  CounterACT research program utilize Research Centers Excellence U54) Cooperative Research Projects U01) support to 5 years translational research.  Chemical threats be covered include pulmonary agents e.g. chlorine, phosgene), toxic industrial chemicals e.g. cyanide, pesticides), chemical nerve agents e.g. sarin, VX), others.  NIH intends commit approximately 12 million per year Fiscal Years 2011, 2012, 2013 fund new and/or competing renewal U01 U54 awards.  Because nature scope the proposed research vary application application, is anticipated the size duration each award also vary. total amount awarded the number awards depend the number, quality, duration, costs the applications received.  is anticipated several NIH Institutes, including National Eye Institute NEI), National Institute Allergy Infectious Diseases NIAID), National Institute Arthritis Musculoskeletal Skin Diseases NIAMS), Eunice Kennedy Shriver National Institute Child Health Human Development NICHD), National Institute Environmental Health Sciences NIEHS), the National Institute General Medical Sciences NIGMS), also participate this funding opportunity announcement.  notice being provided allow potential applicants sufficient time develop responsive projects.  APPLICATIONS NOT BEING REQUESTED THIS TIME. Inquiries Direct inquiries regarding Notice to: David A. Jett, Ph.D. Program Director, NIH CounterACT Research National Institutes Health, NINDS 6001 Executive Blvd. NSC, Room 2177, MSC 9527 Bethesda, MD 20892-9527 Telephone: 301-496-6035 Fax: 301-402-1501 jettd@ninds.nih.gov

Notice of Intent to Publish a Program Announcement for Countermeasures Against Chemical Threats (CounterACT) Exploratory/Developmental Projects in Translational Research (R21)

NOT
Tuesday, September 22, 2009
Saturday, January 1, 2022
NOT-NS-09-018

Funding Opportunity Purpose

Notice Intent Publish Program Announcement Countermeasures Against Chemical Threats CounterACT) Exploratory/Developmental Projects Translational Research R21) Notice Number: NOT-NS-09-018 Key Dates Release Date: September 22, 2009 Issued National Institute Neurological Disorders Stroke NINDS) http://www.ninds.nih.gov) Purpose nbsp; National Institute Neurological Disorders Stroke NINDS) intends issue Program Announcement Special Referral Considerations PAR) the fall 2009 provide support exploratory developmental translational research therapeutics reducing mortality morbidity caused acute exposures chemical threat agents.  Chemical threat agents toxic chemicals could released a deliberate terrorist attack against civilians, by accident natural disaster causing mass casualties.  NIH CounterACT Research Program supports basic, translational, clinical research aimed the discovery and/or identification better therapeutic medical countermeasures against chemical threat agents, facilitates movement through regulatory process www.ninds.nih.gov/counteract).  CounterACT Exploratory/Developmental Projects Translational Research R21) be utilized support 1-2 year pilot studies generate tools proof-of-principle data therapeutics treat exposures chemical threats.  Chemical threats include traditional chemical warfare nerve agents such sarin VX, toxic industrial chemicals such cyanide chlorine, toxic agricultural chemicals such parathion sodium fluoroacetate.  Pilot studies include creation validation screening assays therapy development, identification candidate therapeutics, development preliminary proof-of-principle data the efficacy candidate therapeutics.  Four six awards anticipated, with direct costs limit 250,000 per year.  is anticipated several NIH Institutes, including National Eye Institute NEI), National Institute Allergy Infectious Diseases NIAID), National Institute Arthritis Musculoskeletal Skin Diseases NIAMS), Eunice Kennedy Shriver National Institute Child Health Human Development NICHD), National Institute Environmental Health Sciences NIEHS), the National Institute General Medical Sciences NIGMS), also participate this funding opportunity announcement. notice being provided allow potential applicants sufficient time develop responsive projects.  APPLICATIONS NOT BEING REQUESTED THIS TIME. Inquiries Direct inquiries regarding Notice to: David A. Jett, Ph.D. Program Director, NIH CounterACT Research National Institutes Health, NINDS 6001 Executive Blvd. NSC, Room 2177, MSC 9527 Bethesda, MD 20892-9527 Telephone: 301-496-6035 Fax: 301-402-1501 jettd@ninds.nih.gov

Correction to RFA-NS-08-003, Countermeasures Against Chemical Threats (CounterACT) Advanced Development Cooperative Agreements (U01)

NOT
Wednesday, November 7, 2007
Saturday, January 1, 2022
NOT-NS-08-007

Notice of Intent to Publish Request for Applications for Countermeasures Against Chemical Threats (CounterACT)

NOT
Tuesday, August 14, 2007
Saturday, January 1, 2022
NOT-NS-07-015

Countermeasures against Chemical Threats (Counteract) Preclinical Development Facility

NOT
Monday, March 27, 2006
Saturday, January 1, 2022
NOT-NS-06-006

Pages